(IN BRIEF) SGS announced that Chair of the Board of Directors Calvin Grieder will step down at the company’s Annual General Meeting on March 26, 2026. Grieder, who has served on the Board since 2019 and as Chair since 2020, … Read the full press release
Posted in Business, Industrial, Investment, Management, News, Switzerland, Technology
Tagged AGM 2026, Board of Directors, Calvin Grieder, corporate strategy, Danone, ESG, Four Seasons Hotels and Resorts, Gilbert Ghostine, global business leadership, Governance, leadership transition, Sandoz, SGS, SGS Proposes Gilbert Ghostine as Next Board Chair to Guide Strategy 27 and Future Growth, Strategy 27, testing inspection certification
(IN BRIEF) Sandoz has launched Afqlir®, its biosimilar to aflibercept, across Europe following European Commission approval in 2024. Equivalent in efficacy, safety, and pharmacokinetics to Eylea®, Afqlir® provides a lower-cost treatment option for serious retinal diseases such as nAMD, RVO, … Read the full press release
Posted in Business, Healthcare, Marketing, News, Pharma & Biotech, Switzerland
Tagged aflibercept, Afqlir, anti-VEGF market, biologic medicines, biosimilar portfolio, biosimilars, Christophe Delenta, DME, European Commission approval, European Rollout of Afqlir Marks Major Step in Sandoz Expansion Across Anti-VEGF Ophthalmology Market, Eylea, intravitreal injection, mCNV, nAMD, ophthalmology, retinal diseases, RVO, Sandoz, Sustainable Healthcare, vision loss treatment
(IN BRIEF) Sandoz has announced the US availability of TYRUKO® (natalizumab-sztn), the first FDA-approved biosimilar to Tysabri® for treating relapsing forms of multiple sclerosis and Crohn’s disease. Developed by Polpharma Biologics, TYRUKO® is clinically equivalent to its reference product and … Read the full press release
Posted in Business, Healthcare, Marketing, News, Pharma & Biotech, Switzerland
Tagged affordable biologics, biosimilar growth, Crohn's disease, FDA approval, JCV antibodies, Keren Haruvi, Labcorp partnership, multiple sclerosis, natalizumab-sztn, neurology portfolio, PML risk, Polpharma Biologics, REMS program, Sandoz, TYRUKO, TYRUKO Availability Marks Major Milestone in Affordable MS Care and Sandoz Biosimilar Leadership, Tysabri biosimilar, US launch
(IN BRIEF) Sandoz has signed a 10-year virtual PPA with Elawan Energy to develop 150 MW of new solar capacity in Valladolid, Spain, expected to meet almost 90% of electricity demand for its European operations. This partnership is a key … Read the full press release
Posted in Business, Energy, Gas & Oil, Environment, Financial, Government, Industrial, Infrastructure & Utilities, Investment, Management, Marketing, News, Pharma & Biotech, Science, Spain, Switzerland, Technology
Tagged biosimilar medicines, carbon footprint reduction, Castilla y León, clean energy, Climate Action, decarbonization, Elawan Energy, Europe, European operations, generic medicines, Glenn Gerecke, partnership, pharmaceutical industry sustainability, PPA, renewable energy, Sandoz, SBTi, Science Based Targets initiative, solar energy, sustainability, Valladolid, virtual power purchase agreement
(IN BRIEF) Sandoz has announced the retirement of Francisco Ballester, President of Region International, after 34 years of service, effective March 1, 2025. Francisco has been instrumental in expanding business growth and patient access in markets outside North America and … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged appointment, biosimilars, Business Growth, Chief Executive Officer, commercial strategy, Country President, Francisco Ballester, generics, Global Platform Head, Health Management and Policy Advisory Council, leadership, M&A, Miami Herbert Business School, patient access, Peter Stenico, Pro Generika, Region International, retirement, Richard Saynor, Sandoz, Sandoz Austria, Sandoz Executive Committee
(IN BRIEF) Just – Evotec Biologics and Sandoz have expanded their strategic partnership to advance the development and commercial manufacturing of biosimilars. This enhanced collaboration includes additional biosimilars in Sandoz’s pipeline and ensures long-term supply through Just – Evotec Biologics’ … Read the full press release
Posted in Business, Environment, Financial, France, Germany, Healthcare, Industrial, Infrastructure & Utilities, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged Biosimilar Development, Dr. Matthias Evers, Evotec, France, Just – Evotec Biologics, partnership, Sandoz, Supply Security, sustainability, Switzerland
(IN BRIEF) Novartis has confirmed its plans for a full Spin-off of its Sandoz business, with trading of new Sandoz Group AG shares and ADRs scheduled to begin on October 4, 2023. This comes after receiving shareholder approval and key … Read the full press release
Posted in Business, Financial, Investment, Pharma & Biotech, Switzerland
Tagged ADRs, American Depositary Receipts, Novartis, Novartis ADR, OTCQX®, Sandoz, Sandoz Group AG, SDZ, shareholder, shares, SIX Exchange Regulation, SIX Swiss Exchange, SLI®, spin-off, SPI®, Swiss indices, Swiss Leader Index, Swiss Performance Index
(IN BRIEF) Sandoz, a global leader in generic and biosimilar medicines, has successfully acquired the worldwide brand rights for the systemic antifungal agent Mycamine® (micafungin sodium) from Astellas. This acquisition bolsters Sandoz’s position in the global hospital sector and enhances … Read the full press release
Posted in Business, Healthcare, Industrial, Management, News, Pharma & Biotech, Science, Switzerland
Tagged acquisition, Astellas, Mycamine®, Richard Saynor, Sandoz
(IN BRIEF) Sandoz to commercialize six products exclusively in the US following distribution and collaboration agreement with Adalvo. The products are aimed at treating disorders that affect millions of people in the US each year, including antifungal/antibiotic, oncology, and pulmonary. … Read the full press release
Posted in Business, Healthcare, Management, News, Pharma & Biotech, Switzerland
Tagged Adalvo, Richard Saynor, Sandoz, treatments, US
(IN BRIEF) Sandoz, a global leader in generic and biosimilar medicines, has signed a Memorandum of Understanding to build a new biologics production plant in Lendava, Slovenia, in a move expected to be worth at least USD 400 million. The … Read the full press release
Posted in Business, Financial, Healthcare, Investment, Management, News, Pharma & Biotech, Science, Switzerland
Tagged antibiotics, Biologics Plant, Dr Robert Golob, Glenn Gerecke, investment, Lendava, Novartis, partnership, Richard Saynor, Sandoz, Slovenia
(NOTICIA EN BREVE) Gilbert Ghostine ha sido designado presidente designado de la nueva junta directiva de Sandoz, tras el anuncio de la junta directiva de Novartis. La nueva Junta Directiva de Sandoz se formará en la segunda mitad de 2023, … Read the full press release
Posted in Business, Management, News, Pharma & Biotech, Switzerland
Tagged appointment, cita, Danone, Diageo, Firmenich, Four Seasons Hotels & Resorts, Gilbert Ghostine, leadership, liderazgo, Novartis, Sandoz
(IN BRIEF) Gilbert Ghostine has been appointed as Chairman-designate of the new Board of Directors of Sandoz, following the announcement by Novartis Board of Directors. The new Board of Directors of Sandoz will be formed in the second half of … Read the full press release
Posted in Business, Management, News, Pharma & Biotech, Switzerland
Tagged appointment, Danone, Diageo, Firmenich, Four Seasons Hotels & Resorts, Gilbert Ghostine, leadership, Novartis, Sandoz
(IN BRIEF) Sandoz, a global leader in off-patent (generic and biosimilar) medicines, has signed an agreement to acquire worldwide product rights for leading systemic antifungal agent Mycamine® (micafungin sodium, Funguard® in Japan) from Astellas. This acquisition will reinforce Sandoz’s hospital … Read the full press release
(NOTICIA EN BREVE) Sandoz, líder mundial en medicamentos sin patente (genéricos y biosimilares), ha firmado un acuerdo para adquirir los derechos de producto a nivel mundial del agente antifúngico sistémico líder Mycamine® (micafungina sódica, Funguard® en Japón) de Astellas. Esta … Read the full press release
Sandoz obtiene capacidades y activos significativos en el desarrollo de dispositivos médicos y medicamentos que apuntan a importantes oportunidades de crecimiento en genéricos complejos y respiratorios Las enfermedades respiratorias son la principal causa de muerte y discapacidad e imponen una … Read the full press release
Sandoz gains significant capabilities and assets in medical and drug device development that target major growth opportunities in respiratory and complex generics Respiratory diseases are leading cause of death and disability and impose huge financial burden on patients worldwide Acquisition … Read the full press release
(PRESS RELEASE) BASEL, 15-Mar-2019 — /EuropaWire/ — Sandoz’s current Region Head Europe Francesco Balestrieri has just been appointed ad-interim CEO of Sandoz reporting directly to Vas Narasimhan, CEO, Novartis. The change is made as the current CEO of Sandoz, a … Read the full press release
Posted in Healthcare, Management, News, Pharma & Biotech, Switzerland
Tagged ad-interim CEO, appointment, biosimilar products, CEO, Francesco Balestrieri, generics, leadership, medicine, Novartis, Richard Francis, Sandoz, Sandoz transformation, transformation, transformative treatments, Vas Narasimhan
Sandoz has been certified by the Top Employers Institute for its exceptional employee offerings in Asia Pacific (APAC) The annual, international research undertaken by the Top Employers Institute recognizes leading employers around the world This exclusive certification underlines Sandoz´ commitment … Read the full press release
Posted in Awards, Germany, Management, Pharma & Biotech
Tagged APAC, Asia_Pacific, Australia, CHINA, David Plink, employee, employer, Healthcare, HR, Japan, Joy Xu, Pakistan, Sandoz, THAILAND
European Commission’s (EC) approval based on comprehensive data package confirming that Zessly® matches safety, efficacy and quality of reference medicine Biosimilars such as Zessly enable earlier patient access to important medicines and positively impact healthcare systems Zessly is the third EC … Read the full press release
Posted in European Union, Germany, Healthcare, Pharma & Biotech
Tagged Europe, European Commission, infliximab, Novartis, Richard Francis, Sandoz, Zessly®
Holzkirchen, Germany, 04-May-2018 — /EuropaWire/ — Sandoz, a Novartis division, announced today that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the Biologics Licensing Application (BLA) for its proposed biosimilar rituximab. Sandoz stands behind … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged Biologics Licensing Application, Biosimilar, medicine, Novartis, rituximab, Sandoz, US FDA
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?